Adaptive Biotechnologies Corporation (ADPT)

Adaptive Biotechnologies Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	170.28	185.31	154.34	98.38	85.07
Revenue Growth (YoY)	-8.11%	20.06%	56.88%	15.65%	52.83%
Cost of Revenue	75.55	57.91	49.3	22.53	22.27
Gross Profit	94.72	127.4	105.04	75.85	62.8
Selling, General & Admin	172.51	184.13	169.97	110.89	68.79
Research & Development	122.12	141.76	142.34	116.07	70.71
Other Operating Expenses	27.13	1.7	1.7	1.7	1.7
Operating Expenses	321.76	327.59	314.01	228.67	141.19
Operating Income	-227.04	-200.19	-208.97	-152.82	-78.39
Interest Expense / Income	13.8	4.24	0	0	0
Other Expense / Income	-15.59	-4.23	-1.69	-6.59	-9.79
Pretax Income	-225.25	-200.19	-207.28	-146.23	-68.61
Net Income	-225.25	-200.19	-207.28	-146.23	-68.61
Preferred Dividends	0	0	0	0	0.96
Net Income Common	-225.25	-200.19	-207.28	-146.23	-69.57
Shares Outstanding (Basic)	144	143	140	131	69
Shares Outstanding (Diluted)	144	143	140	131	69
Shares Change	1.31%	1.54%	6.96%	89.71%	447.64%
EPS (Basic)	-1.56	-1.40	-1.48	-1.11	-1.01
EPS (Diluted)	-1.56	-1.40	-1.48	-1.11	-1.01
Free Cash Flow	-167.02	-200.29	-254.47	-168.49	194.2
Free Cash Flow Per Share	-1.16	-1.41	-1.81	-1.28	2.81
Gross Margin	55.63%	68.75%	68.06%	77.10%	73.82%
Operating Margin	-133.33%	-108.03%	-135.39%	-155.33%	-92.15%
Profit Margin	-132.29%	-108.03%	-134.30%	-148.63%	-81.78%
Free Cash Flow Margin	-98.09%	-108.09%	-164.87%	-171.26%	228.28%
EBITDA	-182.3	-167.81	-186.3	-134.49	-60.82
EBITDA Margin	-107.06%	-90.56%	-120.70%	-136.70%	-71.49%
Depreciation & Amortization	29.15	28.15	20.98	11.74	7.79
EBIT	-211.45	-195.95	-207.28	-146.23	-68.61
EBIT Margin	-124.18%	-105.74%	-134.30%	-148.63%	-80.65%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).